Bayer committed 2.2 billion dollars to an Ohio drug plant on Thursday, three days after Washington extended 100 percent pharmaceutical tariffs to the rest of the industry. The timing was not a coincidence, and it is not the last announcement of its kind.
NEW ALBANY, Ohio, October 3, 2026
Bayer AG said Thursday it will invest 2.2 billion dollars in a new pharmaceutical manufacturing campus in New Albany, Ohio, the clearest corporate signal yet that the Section 232 tariffs on patented medicines are reshaping where the world’s largest drugmakers build capacity.
The announcement came 72 hours after the second and final tranche of those tariffs took effect. On September 29, the 100 percent duty on patented pharmaceutical products and active pharmaceutical ingredients extended from the 17 large manufacturers named in Annex III of Proclamation 11020 to every other company importing covered goods into the United States. Mid-sized and smaller manufacturers, importers and distributors that had operated outside the tariff’s reach since July 31 are now inside it.
Bayer, a German company with substantial European manufacturing, sits in the tier of firms for whom the arithmetic has changed most decisively. Whether the Ohio investment buys the company a path to a reduced rate is a question the Commerce Department will answer, and the answer is worth billions.
What Bayer committed to
The project will rise in the New Albany International Business Park outside Columbus, a site that has drawn heavy advanced-manufacturing investment over the past five years.
The company said the campus will create approximately 600 permanent manufacturing positions and support roughly 1,500 construction jobs during the build. Production will focus on oncology, cardiovascular and renal care medicines, three therapeutic areas where Bayer has significant patented portfolios and corresponding US tariff exposure.
The construction timeline is long, which is characteristic of pharmaceutical facilities and important to understanding the tariff calculus. The first module, covering drug substance manufacturing, is targeted to be operational by 2031. The second module, covering drug product manufacturing, is targeted for 2034.
Chief Executive Bill Anderson described the project as a landmark investment underscoring the company’s commitment, framing it around growth and innovation rather than trade policy. Ohio Governor Mike DeWine said the project firmly solidifies Ohio’s place among global biomanufacturing leaders.
State and regional support is substantial. JobsOhio will invest up to 30 million dollars in an Ohio Life Science Training Center scheduled to open in summer 2027, with roughly 8 million dollars more coming from state, city and private partners. Bayer is also pursuing a Job Creation Tax Credit from the Ohio Department of Development.
Investors were unmoved on the day. Bayer shares closed modestly lower, roughly one percent down, reflecting the long payback horizon on a project that will not produce a saleable molecule for five years.
The tariff that prompted it
Proclamation 11020, signed April 2, 2026, imposed Section 232 duties on patented pharmaceuticals on national-security grounds, citing US dependence on foreign production.
The Commerce Department’s underlying investigation found that approximately 53 percent of patented pharmaceutical products distributed in the United States are produced abroad, and that only about 15 percent of patented active pharmaceutical ingredients by volume are manufactured domestically. China supplies an estimated 40 to 45 percent of global API output.
The headline rate is 100 percent. Beneath it sits a ladder of reduced rates that functions less as a tariff schedule than as an industrial-policy instrument.
Companies with a Commerce-approved onshoring plan pay 20 percent, a rate scheduled to step up to 100 percent on April 2, 2030. Companies that pair a Commerce onshoring plan with a Most Favored Nation pricing agreement executed with the Department of Health and Human Services pay zero through January 20, 2029. Imports from the European Union, Japan, South Korea, Switzerland and Liechtenstein carry 15 percent under negotiated trade frameworks. The United Kingdom carries zero under its own arrangement effective July 31, 2026.
Generic pharmaceuticals and biosimilars are exempt for now, though Commerce is required to reassess that treatment within a year. Specialty pharmaceuticals carry zero where the product falls within a defined list including orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and chemical, biological, radiological and nuclear countermeasures, and where the product originates in one of roughly 19 qualifying jurisdictions or meets an urgent US health need. Materials for clinical trials and non-commercial research carry zero under a dedicated tariff provision.
Covered goods are classified under HTSUS headings 9903.04.60 through 9903.04.70 and draw on Annex I product lists spanning Chapters 29 and 30. Guidance issued September 23 and updated September 28 clarified that pharmaceutical articles include finished products, active pharmaceutical ingredients and key starting materials, while inactive ingredients and excipients are not pharmaceutical articles. Importers must report the applicable Chapter 99 classification on every entry, and where more than one rate could apply, the lowest applicable rate governs. Provision 9903.04.61 ceased to be effective for goods entered after 12:01 a.m. Eastern time on September 29.
The investment wave
Bayer’s announcement joins a procession of capital commitments that the administration has pointed to as proof the policy is working.
Industry trackers put total announced US pharmaceutical manufacturing investment for the 2025 to 2030 window somewhere between 370 billion and 480 billion dollars, with roughly 400 billion in commitments attributed to the current presidential term.
Merck has announced approximately 70 billion dollars. Johnson and Johnson roughly 55 billion. Roche and Genentech together around 50 billion. AstraZeneca between 30 billion and 50 billion depending on the accounting. Eli Lilly approximately 27 billion, including consideration of a 5.9 billion dollar API plant in Houston. Smaller but specific projects include a 1 billion dollar Merck biologics facility in Delaware, a 2 billion dollar Regeneron production site in New York, and a 140 million dollar Moderna mRNA facility.
The mechanism connecting tariffs to these announcements is explicit rather than inferred. Pfizer secured a three-year tariff exemption by committing to MFN pricing alongside 70 billion dollars in US research and manufacturing expansion. A group of nine companies including Amgen, Bristol Myers Squibb and GSK agreed to a collective 150 billion dollars in US factory investment while adopting MFN pricing. By the end of August, 26 manufacturers representing approximately 89 percent of the branded market had signed MFN pricing agreements.
That last figure explains an apparent paradox. A 100 percent headline tariff that applies to most of the branded market would be economically catastrophic. In practice, most of the branded market has contracted its way to a lower rate, which is precisely what the tiered structure was designed to produce.
Who is exposed now
The September 29 expansion changed the distribution of pain rather than its aggregate level.
Large manufacturers had 14 months between the proclamation and the deadline to negotiate onshoring plans and pricing agreements. Many did. Mid-sized and smaller firms had the same clock but far less leverage, fewer products over which to amortize a US facility, and in many cases no realistic path to a Commerce-approved onshoring plan at all. A company with a single patented product and 200 million dollars in US revenue cannot build a plant to serve it.
Those firms now face the full 100 percent rate unless a country carve-out or a specialty classification saves them. For a European mid-cap selling a patented therapy into the United States, the 15 percent EU rate is the difference between a viable business and an exit.
The compliance burden is itself significant. Every product requires individual evaluation across three axes: patent status, customs origin and intended use. A single molecule may qualify for zero as clinical trial material, 15 percent as a commercial import from the EU, and 100 percent if sourced through a non-covered jurisdiction. Getting the Chapter 99 reporting wrong on entry creates liquidated-damages exposure independent of the duty itself.
Industry reaction
The Pharmaceutical Research and Manufacturers of America has maintained its opposition, arguing that tariffs will undermine the goal of discovering and manufacturing affordable medicines in the United States.
Generic manufacturers, currently exempt, are watching the one-year reassessment closely. Sandoz Chief Executive Richard Saynor has warned that patients pay the tariff if future measures reach generics, with the practical consequence being either price increases or product discontinuation. Generic economics leave little margin to absorb a duty, and the US generic market has already experienced shortages driven by thin pricing.
Manufacturing executives have consistently flagged the timeline mismatch at the heart of the policy. One industry leader quoted in trade press noted that it takes four years to set up a new API supplier and eight years for regulatory approval. Bayer’s own schedule illustrates the point: a facility announced in 2026 produces drug substance in 2031 and finished product in 2034. The tariff bites now. The capacity arrives in the next decade.
McKinsey survey data gives a sense of how broadly supply chains are reacting. Eighty-two percent of supply-chain leaders reported being affected by tariffs, 43 percent said they plan to shift supply chains toward the United States over a three-year horizon, and 39 percent reported rising supplier costs.
The front-loading effect has been visible in production statistics. Global pharmaceutical output rose 9.1 percent in 2025 as companies and distributors built inventory ahead of the duties. Ireland, a hub for US-bound pharmaceutical exports, saw output jump 41.3 percent. Global pharmaceutical sales grew approximately 9.7 percent over the same period, inflated by stockpiling rather than underlying demand.
Economic impact
The direct cost of the measure depends almost entirely on how much trade flows at the headline rate versus the negotiated rates, and the available evidence suggests most of it flows at negotiated rates.
European Union drug exports to the United States totaled approximately 127 billion dollars in 2024. At the 15 percent EU rate, that trade carries roughly 19 billion dollars in annual duty exposure, a figure that has circulated widely in European industry analysis. At 100 percent it would be unsustainable, which is why the EU rate was a central objective in the trade framework negotiations.
India exports roughly 10.5 billion dollars in pharmaceutical products to the United States annually, overwhelmingly generics, and is therefore largely outside the current measure. That position changes if the generic exemption lapses at reassessment, which is the single largest open question in the policy.
On the domestic side, the announced investment totals are real commitments but should be read carefully. They are multi-year, they include research and development as well as manufacturing, many were in planning before the proclamation, and the capacity they create arrives in the 2029 to 2034 window. Treating them as a near-term substitute for imports overstates what the policy can deliver this decade.
The pricing channel is where consumers encounter the measure. MFN pricing agreements, which most branded manufacturers have now signed, commit companies to align US prices with those in comparator markets, which in principle reduces US list prices. Whether that translates into lower patient costs depends on rebate structures, formulary design and insurer behavior, none of which the tariff reaches.
What it means for importers and US businesses
For pharmaceutical importers, three disciplines matter immediately.
The first is classification. The guidance distinguishing pharmaceutical articles from inactive ingredients and excipients is doing substantial work, and the boundary cases are commercially significant. Companies should document classification positions for every covered SKU now, while the record is fresh, rather than at audit.
The second is rate stacking. With multiple Chapter 99 provisions potentially applicable to the same article, and the lowest applicable rate governing, the compliance task is not to find a rate but to find the best supportable one and evidence it. The September 29 retirement of provision 9903.04.61 is a reminder that the schedule is moving and that entry templates built in August may already be wrong.
The third is the 2030 step-up. The 20 percent onshoring rate is not permanent. It reverts to 100 percent on April 2, 2030, and the zero rate tied to MFN pricing expires January 20, 2029. Any company building a US facility on the strength of a reduced rate should be modeling the cliff, because a plant that comes online in 2031 arrives after the concession it was built to secure has lapsed.
For US businesses outside pharmaceuticals, the Bayer announcement carries a broader lesson about how the current tariff architecture operates. Section 232 duties are not primarily revenue instruments. They are negotiating positions with a published schedule of discounts, and the discounts are available to companies that commit capital domestically and accept conditions on pricing. Industries currently under or approaching Section 232 review, including critical minerals, should expect the same structure.
For construction, engineering and industrial suppliers, the pipeline is tangible. A 2.2 billion dollar pharmaceutical campus generates years of demand for process equipment, cleanroom systems, controls and specialized construction labor. Several of those input categories are themselves tariffed, which means project budgets carry an internal tariff cost the policy does not offset.
What to watch
Three dates define the near term. Commerce’s reassessment of the generic and biosimilar exemption falls due within a year of the proclamation and is the largest single variable in the policy. The MFN zero rate expires January 20, 2029. The onshoring rate steps to 100 percent on April 2, 2030.
Watch also for the next wave of announcements. Bayer will not be the last European manufacturer to put a US flag on a capital plan, and each announcement should be read as a data point about how a specific company assessed its chances of securing a Commerce-approved onshoring plan.
For now the duties are collected at the border, the plants are drawings, and the gap between the two is measured in years.
Ohio’s calculation
The choice of New Albany is not incidental, and it illustrates how tariff-driven onshoring is redistributing industrial investment inside the United States as well as across borders.
Central Ohio has spent a decade assembling the inputs that advanced manufacturing requires: large pre-assembled industrial sites with utility and water capacity already in place, a state economic development corporation able to move quickly on incentives, and a university pipeline that the state puts at roughly 39,000 annual STEM graduates across what it brands the Ohio Discovery Corridor.
Pharmaceutical manufacturing is more demanding than most. Drug substance production requires large volumes of high-purity water, redundant power, and extensive wastewater treatment. Finding sites that can support that profile without multi-year utility construction is the binding constraint on how quickly the industry can actually onshore, and it is a constraint that tariff policy cannot relax.
The JobsOhio training center is an acknowledgment of the second constraint. Six hundred manufacturing positions in a regulated pharmaceutical environment require qualified operators, quality personnel and validation engineers who do not currently exist in the local labor pool in sufficient numbers. The center is scheduled to open in summer 2027, roughly four years before the first module produces anything, which is about the right lead time to train a workforce from scratch.
Other states are competing on the same terms. North Carolina, Indiana, Delaware and Texas have all landed significant pharmaceutical capital over the past 18 months. The policy is therefore producing a domestic incentive competition alongside the international one, with states bidding against each other for projects that the tariff made inevitable somewhere in the United States.
The question the policy has not answered
For all the capital being committed, one issue remains unresolved and it may determine whether the Section 232 pharmaceutical program is judged a success.
The stated national-security rationale is dependence on foreign production, with the sharpest version of that concern attaching to active pharmaceutical ingredients and key starting materials, where China’s share of global output is estimated at 40 to 45 percent. Yet the tariff falls on patented pharmaceuticals, while generics and biosimilars are exempt, and it is in generics that the API dependence is most acute and the supply fragility most demonstrated.
That mismatch is deliberate in the short run. Applying a 100 percent duty to generics would have produced immediate shortages and price spikes in exactly the medicines where the US has the least slack, which is the outcome Sandoz and others have warned about. But it means the measure currently taxes the segment of the market with the most pricing power and the greatest ability to build domestic capacity, while leaving untouched the segment where the security concern is strongest.
Commerce’s reassessment of the generic exemption, due within a year of the April 2 proclamation, is where that tension has to be resolved. Industry expects some form of targeted action, perhaps on a defined list of essential medicines or key starting materials rather than a blanket extension of the 100 percent rate. Importers of generics and their US distributors should be preparing for that review now, including by documenting current sourcing, identifying qualified alternative suppliers, and modeling the margin impact of duties at several rate levels.
A note on the broader pattern
The pharmaceutical program is the most developed example of a template the administration has now applied across several sectors: a high headline Section 232 rate, a schedule of reduced rates conditioned on domestic investment, country-specific rates negotiated bilaterally, and carve-outs for products where immediate supply disruption would be unacceptable.
The same structure appears in the polysilicon and solar action, where a 15 percent duty is paired with minimum import prices of 21 dollars per kilogram for polysilicon, 100 dollars per kilogram for ingots and wafers, 22 cents per watt for cells and 38 cents per watt for modules, effective December 4, alongside a Commerce-administered relief program for domestic producers meeting approved investment commitments.
Companies in sectors that may face future Section 232 action should read these programs as a roadmap. The window in which a reduced rate can be negotiated is the window between the investigation’s initiation and the proclamation’s effective date, and it is measured in months. Firms that waited in pharmaceuticals are the ones paying 100 percent today.